Stockscreener 앱 받기
54.80
1.03%
-0.57
시간 외 거래:
54.60
-0.20
-0.36%
전일 마감가:
$55.37
열려 있는:
$55.66
하루 거래량:
907.93K
Relative Volume:
0.57
시가총액:
$6.97B
수익:
$947.36M
순이익/손실:
$392.47M
주가수익비율:
18.15
EPS:
3.02
순현금흐름:
$392.71M
1주 성능:
+3.79%
1개월 성능:
+12.76%
6개월 성능:
+0.09%
1년 성능:
+52.05%
1일 변동 폭
$54.77
$55.73
1주일 범위
$52.23
$55.79
52주 변동 폭
$33.15
$65.53
Halozyme Therapeutics Inc Stock (HALO) Company Profile
명칭
Halozyme Therapeutics Inc
전화
(858) 794-8889
주소
12390 EL CAMINO REAL, SAN DIEGO, CA
HALO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
54.80 | 6.97B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-06-07 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | 개시 | TD Cowen | Outperform |
| 2023-07-24 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-07-24 | 개시 | H.C. Wainwright | Buy |
| 2023-05-10 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | 재개 | Berenberg | Buy |
| 2023-03-16 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | 재개 | Morgan Stanley | Overweight |
| 2022-11-28 | 개시 | Wells Fargo | Overweight |
| 2022-09-09 | 개시 | Morgan Stanley | Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2021-06-14 | 개시 | Evercore ISI | Outperform |
| 2021-05-17 | 개시 | SVB Leerink | Outperform |
| 2021-05-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | 재확인 | The Benchmark Company | Buy |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-07-01 | 개시 | The Benchmark Company | Buy |
| 2020-02-05 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | 개시 | Goldman | Buy |
| 2019-11-05 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2018-10-19 | 재개 | Piper Jaffray | Neutral |
| 2018-05-11 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2018-01-24 | 개시 | Goldman | Neutral |
| 2017-10-16 | 재확인 | Piper Jaffray | Overweight |
| 2017-01-06 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2016-11-03 | 개시 | Deutsche Bank | Buy |
| 2015-12-04 | 개시 | Wells Fargo | Outperform |
| 2015-11-18 | 개시 | Citigroup | Buy |
| 2015-09-22 | 개시 | Barclays | Overweight |
| 2015-06-22 | 재확인 | JP Morgan | Overweight |
| 2015-03-03 | 재확인 | UBS | Buy |
| 2015-02-18 | 재확인 | MLV & Co | Buy |
| 2015-01-08 | 재확인 | MLV & Co | Buy |
모두보기
Halozyme Therapeutics Inc 주식(HALO)의 최신 뉴스
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Sees Large Growth in Short Interest - MarketBeat
Empirical Asset Management LLC Invests $1.09 Million in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Bernzott Capital Advisors Purchases New Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Outlook Wealth Advisors LLC Makes New Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Converting IV-drip Medications into Shots -January 16, 2025 at 12:29 pm EST - Marketscreener.com
(HALO) Technical Data - Stock Traders Daily
Research Analysts Offer Predictions for HALO FY2025 Earnings - MarketBeat
Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines - Yahoo Finance
Wells Fargo & Company Has Lowered Expectations for Halozyme Therapeutics (NASDAQ:HALO) Stock Price - Defense World
5 Biotech Stocks Worth Adding to Your Portfolio in 2025 - Zacks Investment Research
Q1 Earnings Forecast for HALO Issued By Leerink Partnrs - MarketBeat
Analyst Expectations For Halozyme Therapeutics's Future - Benzinga
Halozyme Therapeutics (NASDAQ:HALO) Price Target Cut to $57.00 by Analysts at Wells Fargo & Company - MarketBeat
Analysts Set Halozyme Therapeutics, Inc. (NASDAQ:HALO) Price Target at $61.44 - MarketBeat
Piper Sandler Increases Halozyme Therapeutics (NASDAQ:HALO) Price Target to $53.00 - Defense World
HC Wainwright Forecasts Strong Price Appreciation for Halozyme Therapeutics (NASDAQ:HALO) Stock - Defense World
HALO Raises 2025 Financial Guidance, Keeps 2024 View, Stock Up - MSN
Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why - MSN
Halozyme raises 2025 guidance, announces $250M stock buyback - MSN
Halozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $53.00 - MarketBeat
Q3 EPS Estimate for Halozyme Therapeutics Lifted by Analyst - MarketBeat
Are Options Traders Betting on a Big Move in Halozyme (HALO) Stock? - MSN
Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today - Yahoo Finance
Q1 EPS Forecast for Halozyme Therapeutics Raised by Analyst - MarketBeat
Earnings call transcript: Halozyme Q3 2024 boosts guidance amid strong growth - Investing.com India
First Hawaiian Bank Purchases 20,700 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Everence Capital Management Inc. Purchases New Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Defense World
Halozyme Therapeutics (NASDAQ:HALO) Shares Gap UpTime to Buy? - MarketBeat
Halozyme Announces Takeda Received Regulatory Approval for HYQVIA® 10% Subcutaneous Injection Set with ENHANZE® in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia - Kilgore News Herald
Halozyme Therapeutics (NASDAQ:HALO) Updates FY 2025 Earnings Guidance - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) Updates FY 2024 Earnings Guidance - MarketBeat
Halozyme Therapeutics, Inc. Raises Earnings Guidance for the Full Year 2025 -January 08, 2025 at 07:00 am EST - Marketscreener.com
Halozyme Therapeutics (NASDAQ:HALO) Updates FY24 Earnings Guidance - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) Releases FY25 Earnings Guidance - MarketBeat
Halozyme Therapeutics, Inc. Reiterates Earnings Guidance for the Full Year 2024 - Marketscreener.com
Halozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance - PR Newswire
Halozyme Therapeutics director Jeffrey Henderson sells $500,060 in stock - Investing.com India
Insider Sell: Jeffrey Henderson Sells 10,000 Shares of Halozyme Therapeutics Inc (HALO) - GuruFocus.com
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Jeffrey William Henderson Sells 10,000 Shares - MarketBeat
The Zacks Rank Explained: How to Find Strong Buy Medical Stocks - Yahoo Finance
Zacks.com featured highlights include Leidos, Amazon.com, Halozyme Therapeutics and BioMarin Pharmaceutical - Yahoo Finance
Halozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance - The Malaysian Reserve
Halozyme Therapeutics (HALO) Shares Cross Above 200 DMA - Nasdaq
Halozyme: 'Accidental' Business Model Has Exciting Upside Opportunities In 2025 - Seeking Alpha
Halozyme: Recent Approvals Alter My Appetite (NASDAQ:HALO) - Seeking Alpha
FDA Approves BMS’ Opdivo Qvantig with Halozyme’s ENHANZE Technology - Contract Pharma
Halozyme Therapeutics' (HALO) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Halozyme Therapeutics Inc (HALO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.65%
4.62%
자본화:
|
볼륨(24시간):